Cite

HARVARD Citation

    Ager, C. et al. (2021). High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege. Journal for immunotherapy of cancer. 9 (8), p. . [Online]. 
  
Back to record